Evidence map›Paper›PMID 26508022›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women.

Shweta Sharma, Showket Hussain, Kartik Soni, Pallavi Singhal, Richa Tripathi, V G Ramachandran, Sonal Sharma, Shukla Das, Beena Pillai, Mausumi Bharadwaj

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. miR-138 expression in oral herpes simplex and its effect on ICP0.Experimental and therapeutic medicine · 2019
    Article
  8. Article
  9. Review
  10. Article
  11. Evaluation of miR-711 as Novel Biomarker in Prostate Cancer ProgressionAsian Pacific journal of cancer prevention : APJCP · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shweta SharmaDivision of Molecular Genetics & Biochemistry, Institute of Cytology & Preventive Oncology, I-7 Sector 39, Noida, 201301, India.
Showket HussainDivision of Molecular Oncology, Institute of Cytology & Preventive Oncology, I-7 Sector 39, Noida, 201301, India.
Kartik SoniInstitute of Genomics and Integrated Biology, Mall Road, New Delhi, India.
Pallavi SinghalDivision of Molecular Genetics & Biochemistry, Institute of Cytology & Preventive Oncology, I-7 Sector 39, Noida, 201301, India.
Richa TripathiDivision of Molecular Genetics & Biochemistry, Institute of Cytology & Preventive Oncology, I-7 Sector 39, Noida, 201301, India.
V G RamachandranDepartment of Microbiology, UCMS & GTB Hospital, Dilshad Garden, New Delhi, India.
Sonal SharmaDepartment of Pathology, UCMS & GTB Hospital, Dilshad Garden, New Delhi, India.
Shukla DasDepartment of Microbiology, UCMS & GTB Hospital, Dilshad Garden, New Delhi, India.
Beena PillaiInstitute of Genomics and Integrated Biology, Mall Road, New Delhi, India.
Mausumi BharadwajDivision of Molecular Genetics & Biochemistry, Institute of Cytology & Preventive Oncology, I-7 Sector 39, Noida, 201301, India. mausumi.bharadwaj@gmail.com.
Guru Teg Bahadur Hospital · INInstitute of Cytology and Preventive Oncology · INInstitute of Genomics and Integrative Biology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the role of miRNAs in HPV-mediated cervical pre-cancer and cancer cases in Indian population. We analysed the HPV infection and its genotypes in uterine cervical pre-cancer (n = 80), cancer (n = 200) and normal cervical samples (n = 150) by consensus sequence PCR followed by type specific PCRs. Also, microRNA profiling was done in a subset of cervical pre-cancer (n = 20), cancer cases (n = 50) and normal samples (n = 30) by real-time quantitative PCR (qRT-PCR). The prevalence of HPV infection in pre-cancer was found to be 81 % (65/80) and 94 % (188/200) in cancer cases, with most predominant high-risk HPV type-16 (HR-HPV-16) in 83 % of cancer and 91 % of pre- cancer cases, respectively. Whereas in controls, the HPV infection was found to be very low (5 %). The miRNA profiling revealed that in cervical pre-cancer, 100 miRNAs were significantly (p < 0.001) differentially expressed with 70 miRNAs upregulated and 30 miRNAs downregulated. In cervical cancer cases, 383 miRNA were found to be differentially expressed (p < 0.001), of which 350 miRNAs were upregulated and 33 miRNAs were downregulated. We also observed that 182 miRNAs were differentially expressed (p < 0.001) in HPV-16/18-positive (SiHa/HeLa) cell lines compared with HPV-negative (C33A) cell line. In addition, we identified the novel microRNAs such as miR-892b, miR-500, miR-888, miR-505 and miR-711 in cervical precancerous lesions and cervical cancer cases in Indian population. Taken together, the study demonstrates a crucial role of microRNAs in cervical cancer, which may serve as potential early diagnostic markers for cervical carcinogenesis.

Indexed as

Biomarkers, TumorCarcinogenesisCase-Control StudiesDown-RegulationEarly Detection of CancerFemaleGene Expression Regulation, NeoplasticHeLa CellsHumansMicroRNAsPapillomavirus InfectionsSquamous Intraepithelial Lesions of the CervixTranscriptomeUp-RegulationUterine Cervical DysplasiaUterine Cervical NeoplasmsBiomarkers, TumorMicroRNAsCervical cancerHPVMicroRNAs

Identifiers

PMID26508022
OpenAlexW1853245536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.